Transcript19 Sep 2025 08:58
For iSCIB1+, we're seeing the progression-free survival, the PFS at a level of 78% in our target population. If you compare this to historic doublet checkpoints or standard of care, that's around 46%. So there's a whopping difference that we're seeing here.
We're seeing T-cell responses in 72% of patients to both TRP-2 and gp100. Why do I emphasize that? Well, that means because we're seeing T-cells to both of those epitopes that reduces the likelihood of immune escape. So it gives the prospect of a longer-term immune control. use that as a selection tool to select for patients into the Phase III that we know will respond. This basically enhances the chances of success. And it's very, very rare that you have a selection marker for an I-O therapy.
GlyMab Therapeutics,to me, there's a little gold mine there
I'm pleased how Modi is going. We are seeing benefit in patients from Modi. highly anticipated clinical data from Modi is anticipated in Q4 in renal cell carcinoma in combination with the checkpoint inhibitors
we believe we have the right data set to generate partnering interest.
So is it safe to assume that you're confident in either a partnership or financing before that trial starts or the randomized study start?
I'd say so, Ed. So yes, we are confident. We have the bulk of the data. We are in active conversations
The actual study of funding the study we will evaluate our options following the active conversations we're having with partners right now. So based on those conversations, based on their feedback as well as the confirmation from the regulators that we've got the right study design, we will come back and update you on what that right financing will be.
with this data set and our push on regulatory conversations, we're very confident that we will have serious conversations about partnering and partnering in the broader sense. And also possibilities around investment further.
HTTPS://seekingalpha.com/article/4822076-scancell-holdings-plc-scnlf-q4-2025-earnings-call-transcript
Sign In
Follow the stocks
